LATEST ISSUE: Change – starts slow, then moves faster
Things remain exciting in the realm of diabetes tech, and by that I also mean the realm of overall diabetes care. Tools and choices are
Things remain exciting in the realm of diabetes tech, and by that I also mean the realm of overall diabetes care. Tools and choices are
Diabetes UK’s free online diabetes tech conference is back for its fifth year on Saturday, 14 October 2023. Previously known as the ‘Type 1 and
Eli Lilly and Co has announced that it will buy privately held Versanis for potentially up to $1.93bn to strengthen its position in the fast-growing
A smartphone-based app designed to deliver cognitive-behavioral therapy (CBT) to adults with Type 2 diabetes has received marketing approval as a class II medical device from the
It’s an ongoing debate in the diabetes world: is it ideal to consume a very low carbohydrate diet, or better to go with moderate amounts
The U.S. Food and Drug Administration (FDA) has now approved Lantidra, the first allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells for
The FDA has approved the Lantidra allogeneic pancreatic islet cellular therapy developed by CellTrans to treat diabetes. This is the first approval of a donor
Beta Bionics has raised private funding of $100m to support commercialization and further development of iLet Bionic Pancreas, its recently-authorized automated insulin dosing (AID) system, which
Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.
New data suggests that significant reductions in HbA1c have occurred over time among adults with Type 1 diabetes as their use of diabetes technology has